In:
Journal of Immunology Research, Hindawi Limited, Vol. 2018 ( 2018-12-16), p. 1-12
Abstract:
Limited information is currently available concerning HLA class I antigen abnormalities in sarcomatoid hepatocellular carcinoma (sHCC). Here, we have analyzed the growth characteristics and HLA class I antigen status of four sHCC cell lines (sHCC29, sHCC63, sHCC74, and SAR-HCV); the first three were newly established in this study. Among the four, sHCC29 showed the highest growth rate in vitro and tumorigenicity in NOD-SCID mice. Unlike sHCC74 and SAR-HCV, both sHCC29 and sHCC63 had no detectable surface HLA class I antigen expression, alongside undetected intracellular β 2 -microglobulin ( β 2 m) and marked HLA class I heavy chain and selective antigen-processing machinery (APM) component downregulation. The loss of β 2 m in sHCC29 and sHCC63 was caused by a 〉 49 kb deletion across the B2M locus, while their downregulation of APM components was transcriptional, reversible by IFN- γ only in several components. β 2 m was also undetected in the primary HCC lesions of the patients involved, indicating its in vivo relevance. We report for the first time HLA class I antigen loss with underlying B2M gene deficiency and APM defects in 50% (2 of 4) of the sHCC cell lines tested. These findings may have implications for a proper design of T cell immunotherapy for the treatment of sHCC patients.
Type of Medium:
Online Resource
ISSN:
2314-8861
,
2314-7156
DOI:
10.1155/2018/8363265
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2018
detail.hit.zdb_id:
2817541-4